Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genedrive ( (GB:GDR) ) has provided an announcement.
Genedrive plc has announced the publication of the NHS implementation guide for CYP2C19 genotype testing, which supports prescribing decisions for stroke patients. The guide highlights the advantages of rapid testing, such as immediate results that facilitate timely treatment decisions, reducing the need for follow-up appointments. The Genedrive® CYP2C19 ID Kit is noted as the preferred rapid testing platform, and the company has been focusing on commercial efforts at the trust and Integrated Care Board level, as rapid testing funding must be sourced locally.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercializes rapid, low-cost, and easy-to-use point-of-care testing platforms for diagnosing genetic variants. These platforms provide clinicians with crucial genetic information to make informed decisions on medication choices and dosages, particularly in emergency healthcare settings. The company has launched the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both of which are recommended by NICE for use in the UK NHS.
Average Trading Volume: 56,858,051
Technical Sentiment Signal: Sell
Current Market Cap: £10.55M
See more data about GDR stock on TipRanks’ Stock Analysis page.